Template:Factor Xa Inhibitor Reversal: Difference between revisions
| Line 8: | Line 8: | ||
| [[Apixaban]] (Eliquis®)||8-15 hrs (longer in renal impairment)||No|| | | [[Apixaban]] (Eliquis®)||8-15 hrs (longer in renal impairment)||No|| | ||
*If ingested within 2 hours, administer activated charcoal | *If ingested within 2 hours, administer activated charcoal | ||
*4-factor PCC (Kcentra™)^ | *4-factor [[PCC]] (Kcentra™)^ | ||
**25units/kg—max 2500 units for treatment of documented intracranial hemorrhage | **25units/kg—max 2500 units for treatment of documented intracranial hemorrhage | ||
**50 units/kg—max 5000 units for all other life-threatening bleeds | **50 units/kg—max 5000 units for all other life-threatening bleeds | ||
Revision as of 10:53, 24 September 2016
Factor Xa Inhibitor Reversal
| Anticoagulant | Half-life | Removed by HD | Strategies to reverse or minimize anticoagulant effects |
| Apixaban (Eliquis®) | 8-15 hrs (longer in renal impairment) | No |
|
| Edoxaban (Savaysa®) | 10-14 hrs (longer in renal impairment) | ~ 25% | As above |
| Rivaroxaban (Xarelto®) | 9-13 hrs (longer in renal impairment) | No | As above |
| Fondaparinux (Arixtra®) | 17-21 hrs (significantly longer in renal impairment) | No | 4-factor PCC (Kcentra™)^ 50 units/kg—max 5000 units |
^Off-label